LogicBio Therapeutics (NASDAQ:LOGC) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.
Risk and Volatility
LogicBio Therapeutics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500.
This is a summary of recent recommendations for LogicBio Therapeutics and bluebird bio, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
LogicBio Therapeutics presently has a consensus target price of $23.00, suggesting a potential upside of 145.20%. bluebird bio has a consensus target price of $134.99, suggesting a potential upside of 62.41%. Given LogicBio Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe LogicBio Therapeutics is more favorable than bluebird bio.
Earnings and Valuation
This table compares LogicBio Therapeutics and bluebird bio’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|LogicBio Therapeutics||N/A||N/A||-$17.62 million||($3.04)||-3.09|
|bluebird bio||$54.58 million||84.26||-$555.63 million||($10.68)||-7.78|
LogicBio Therapeutics has higher earnings, but lower revenue than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares LogicBio Therapeutics and bluebird bio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
55.9% of LogicBio Therapeutics shares are owned by institutional investors. 49.9% of LogicBio Therapeutics shares are owned by insiders. Comparatively, 3.0% of bluebird bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
LogicBio Therapeutics beats bluebird bio on 8 of the 13 factors compared between the two stocks.
About LogicBio Therapeutics
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
About bluebird bio
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; and TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.